Chemotherapy resistant sarcoma treated with whole body hyperthermia (WBH) combined with 1-3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)

References

• Antman K. H., Montella D., Rosenbaum C., Schwen M. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treatment Reports 1985; 69: 499–504
   PubMedGoogle Scholar
• Antman K. H., Ryan L., Elias A., Sherman D., Grier H. E. Response to Ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. Journal of Clinical Oncology 1989; 7: 126–131, (errata pp. 1369)
   PubMed Web of Science ®Google Scholar
• Aronin P. A., Haley M. S., Rudnick S. A., Dudka L., Donahue J. F., Selker R. G., Moore P. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. New England Journal of Medicine 1980; 303: 183–191
   PubMed Web of Science ®Google Scholar
• Bull J. M. C. Review of systemic hyperthermnia. Frontiers in Radiation Therapy and Oncology, J. Vaeth. Karger Publishing, Basel 1984; Vol 18: 171–176, 1984
   Google Scholar
• Bull J. M. C., Lees D., Schuette W., Whang-Peng J., Smith R., Bynum G., Atkinson E. R., Gottdiener J. S., Gralnick H. R., Shawker T. G., De Vita V. T., Jr. Whole body hyperthermia: a phase I trial of a potential adjuvant to chemotherapy. Annals of Internal Medicine 1979; 90: 317–323
   PubMed Web of Science ®Google Scholar
• Bull J. M. C., Mansfield B., Bertoli L., Smith R., Glatstein E. An unusual whole body hyperthermia (WBH) case history. Proceedings of the American Society of Clinical Hyperthermia 1988; 4: 23
   Google Scholar
• Bull J. M. C., Ohno S., Strebel R. F., Stephens C. S., Travis E. L., Klostergaard J., Tomasovic S., Khokhar A. R., Siddik Z. H. Antitumor effect and normal tissue toxicity of tumor nectrosis factor combined with whole body hyperthermia and cisplatin or carboplatin in rats. Proceedings of the 9th International Congress of Radiation Research, Toronoto, 1991; 106
   Google Scholar
• Cavaliere R., Ciocatto E. C., Giovanella B. C., Heidelberger C., Johnson R. O., Moricca G., Rossi-Fanelli A. Selective heat sensitivity of cancer cells (biochemical and clinical studies). Cancer 1967; 20: 1351–1381
   PubMed Web of Science ®Google Scholar
• Chang A. E., Rosenberg S. A., Glatstein E. J., Antman K. H. Sarcomas of soft tissues. Cancer Principles & Practice of Oncology, V. T. DeVita, Jr., S. Hellman, S. A. Rosenberg. J. B. Lippincott Co., Philadelphia 1989; Vol 1: 1345–1398
   Google Scholar
• Cronau L. H., Bourke D. L., Bull J. M. C. General anesthesia for whole body hyperthermia. Cancer Research 1984; 44: (Suppl), 4873–4877
   Web of Science ®Google Scholar
• Dirix L. Y., Van-Oosterom J. The role of ifosfamide in the treatment of adult soft tissue sarcomas, Swing's sarcoma and osteosarcoma: a review. Seminars in Oncololgy 1990; 17: 50–57
   PubMed Web of Science ®Google Scholar
• Hahn G. M. Potential for therapy of drugs and hyperthermia. Cancer Research 1979; 39: 2264–2268
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1959; 53: 457–481
   Web of Science ®Google Scholar
• Katz M. F., Glick J. H. Nitrosoureas: a reappraisal of clinical trials. Cancer Clinical Trials 1979; 2: 297–316
   PubMedGoogle Scholar
• Lees D. E., Kim Y. D., Dubois M., Bull J. M., Smith R., Schuette W. H., Macnamara T. E. Internal organ hypoxia during hyperthermic cancer therapy in humans. National Institute on Drug Abuse Research Monogram 1982; 61: 399–400
   Google Scholar
• Lotze M. T., Matory Y. L., Rayner A. A., Ettinghausen S. C., Vetto J. T., Seip C. A., Rosenberg S. A. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58: 2764–2722
   PubMed Web of Science ®Google Scholar
• Marti C., Kroner T., Remagen W., Berchtold W., Cserhati M., Varini M. High dose ifosfamide in advanced osteosarcoma. Cancer Treatment Reports 1985; 69: 115–117
   PubMedGoogle Scholar
• Mutch D. G., Powell C. B., Kao M. S., Collins J. L. In vitro analysis of the anticancer potential of tumor necrosis factor in combination with cisplatin. Gynecological Oncology 1989; 34: 328–333
   PubMed Web of Science ®Google Scholar
• Nauts H. C., Swift W. E., Coley B. L. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D. Reviewed in the light of modern research. Cancer Research 1946; 6: 205–216
   PubMed Web of Science ®Google Scholar
• Neilan B. A., Henle K. J. In vivo response of murine RIF tumors to thermochemotherapy. Journal of Medicine 1989; 20: 107–12
   PubMedGoogle Scholar
• Oken M. H., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982; 5: 649–665
   PubMed Web of Science ®Google Scholar
• Palma J., Bailani S., Freiman A., Sinks L., Holland J. Treatment of metastatic Ewing's sarcoma with BCNU. Cancer 1972; 30: 909–913
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Muul L. M., Leitmann S., Chang A. E., Vetto J. T., Seip C. A., Rosenberg S. A. A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2. Surgery 1986; 100: 262–271
   PubMed Web of Science ®Google Scholar
• Selker R. G., Jacobs S. A., Moore P. B. Interstitial pulmonary fibrosis as a complication of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) as therapy. Neurosurgery 1980; 7: 580–585
   Web of Science ®Google Scholar
• Tomasovic S. P., Barta M., Klostergaard J. Neutral red uptake and clonogenic survival assays of the hyperthermic sensitization of tumor cells to tumor necrosis factor. Radiation Research 1989; 119: 325–337
   PubMed Web of Science ®Google Scholar
• Vogel C. L., Clements D., Waname A. K., Toya T., Primack A., Kyalwazi S. Phase II clinical trials of BCNU (NSC-409962) and bleomycin (NSC-12056) in the treatment of Kaposi's sarcoma. Cancer Chemotherapy Reports 1973; 57: 325–333
   PubMedGoogle Scholar
• Wadler S., Schwartz E. L. Antineoplastic activity of combination interferon and cytotoxic agents against experimental and human malignancies. A review. Cancer Research 1990; 50: 3473–3486
   PubMed Web of Science ®Google Scholar
• Wallner K. E., DeGregorio M. W., Li G. C. Hyperthermia potentiation of cis- diamminedichloroplatinum (II) cytotoxicity in Chinese hamster ovary cells resistant to drug. Cancer Research 1986; 46: 6242–6245
   PubMed Web of Science ®Google Scholar
• Wallner K. E., Banda M., Li G. C. Hyperthermia enhancement of cell killing by mitomycin C in mitomycin C-resistant Chinese hamster ovary cells. Cancer Research 1987; 47: 1308–1312
   PubMed Web of Science ®Google Scholar
• Weiss R. B., Pposter D. S., Penta J. S. The nitrosoureas and pulmonary toxicity. Cancer Treatment Reports 1985; 8: 111–125
   Google Scholar
• Wondergem J., Strebel F. R., Siddik Z. H., Newman R. A., Bull J. M. C. The effects of anesthetics on cisplatinum-induced toxicity at normal temperatures and during whole-body hyperthermia: the influence of NaCl concentration of the vehicle. International Journal of Hyperthermia 1988; 4: 643–654
   PubMed Web of Science ®Google Scholar
• Yershalmi A., Tovey M. G., Gresser I. Antitumor effect of combined interferon and hyperthermia in mice. Proceedings of the Society of Experimental Biology and Medicine 1982; 169: 413–415
   PubMed Web of Science ®Google Scholar